Piper Sandler analyst David Westenberg raised the firm’s price target on GeneDx (WGS) to $160 from $140 following quarterly results. The firm keeps an Overweight rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: